Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.